David H. Kirn

Biochemistry, Genetics and Molecular Biology · Life Sciences

73h-index21.7kcitations232works3.22yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(187), CAR-T cell therapy research(86), Cancer Research and Treatments(85), Viral Infectious Diseases and Gene Expression in Insects(75), RNA Interference and Gene Delivery(34)

Publications232 total

Intravenous Oncolytic Vaccinia Expressing Transgenes for Enhanced Safety, Inhibition of Shedding and Systemic Cancer Immunotherapy
Molecular Therapy Oncology·2026Open Access
Design and Characterization of 4D-710, an Aerosolized Gene Therapy for Cystic Fibrosis Lung Disease
American Journal of Respiratory Cell and Molecular Biology·2025
Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies
Investigative Ophthalmology & Visual Science·2024· 15 citedOpen Access
344 Transgene expression and CFTR channel function in human bronchial epithelial cells after addition of CFTR modulators and 4D-710
Journal of Cystic Fibrosis·2024
WS06.01 CFTR transgene expression in airway epithelial cells following aerosolized administration of the AAV-based gene therapy 4D-710 to adults with cystic fibrosis lung disease
Journal of Cystic Fibrosis·2024· 1 cited
Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies
Journal of Clinical Investigation·2023· 111 citedOpen Access
WS05.01 AAV mediated gene therapy for cystic fibrosis: interim results from a phase 1/2 clinical trial
Journal of Cystic Fibrosis·2023· 3 citedOpen Access
Supplemental methods from Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms
2023Open Access
Supplemental Figures 1-9 from Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms
2023Open Access
Supplemental methods from Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms
2023Open Access
Supplemental Figures 1-9 from Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms
2023Open Access
Data from Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms
2023Open Access
Data from Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms
2023Open Access
Supplementary Methods from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Supplementary Figure 3 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Supplementary Figure 2 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Data from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Supplementary Figure 2 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Supplementary Table 1 from Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
2023Open Access
Supplementary Figure Legend from Preventing Postoperative Metastatic Disease by Inhibiting Surgery-Induced Dysfunction in Natural Killer Cells
2023Open Access
page 1 of 12Next →

Frequent Co-authors

John C. Bell(17), Caroline J. Breitbach(13), Carla Heise(10), Anne Moon(9), Tae-Ho Hwang(9), Manijeh Daneshmand(8), James M. Burke(7), Kelley A. Parato(7), Theresa Falls(7), Britta Randlev(6), Ta‐Chiang Liu(6), Steve H. Thorne(6), Jean‐Simon Diallo(5), Frank McCormick(4), John Nemunaitis(4), Ian Ganly(4), L. Romel(4), Tae-Ho Hwang(4), Fabrice Le Bœuf(4), Harold Atkins(4)